Violations of federal securities laws as a result of a series of materially false statements. According to the Complaint, Defendants made false and/or misleading statements regarding IsoRay's Celsium-131 isotope seeds and mesh for the treatment of non-small cell lung cancers. When the true details entered the market, shares of IsoRay fell $1.10 per share, or by more than 35%, to close at $2.02 per share on May 21, 2015, damaging investors. Filed in C.D. Cal.
Lead Plaintiff Deadline: The deadline to file for lead plaintiff in this action is 7/21/2015.
Join This Action: To apply to join this action and be represented by Shepherd, Finkelman, Miller & Shah, LLP, please click here for a certification form to submit your information.
Send Us Information: If you have information about this action that you would like to provide us, please click here.